List of Excipients in Branded Drug RIZATRIPTAN BENZOATE ODT

Generic Drugs Containing RIZATRIPTAN BENZOATE ODT

Company	Ingredient	NDC	Excipient
Direct Rx	rizatriptan benzoate odt	72189-341	ASPARTAME
Direct Rx	rizatriptan benzoate odt	72189-341	CELLULOSE, MICROCRYSTALLINE
Direct Rx	rizatriptan benzoate odt	72189-341	CROSPOVIDONE
Direct Rx	rizatriptan benzoate odt	72189-341	MANNITOL

What are the Most Frequently-Used Excipients in RIZATRIPTAN BENZOATE ODT?

# Of NDCs	Excipient
2	ASPARTAME
1	CARBOXYMETHYLCELLULOSE CALCIUM
2	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE

Rizatriptan Benzoate ODT Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Rizatriptan benzoate orally disintegrating tablets, or ODTs, are an established generic opportunity with low formulation risk and limited current patent barriers. The commercial advantage is not molecule ownership. It is differentiated product design: rapid disintegration, acceptable taste, low moisture sensitivity, simple packaging, and broader patient access through aspartame-free, gelatin-free, or sugar-free formulations.

The reference product, Maxalt-MLT, uses a rapidly disintegrating matrix containing gelatin, mannitol, glycine, aspartame, and peppermint flavor. A competing product can pursue a lower-cost compressed ODT, a more robust freeze-dried tablet, or a differentiated excipient system designed for patients who cannot use phenylalanine-containing aspartame or animal-derived gelatin.

What is rizatriptan benzoate ODT?

Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist used for the acute treatment of migraine attacks, with or without aura, in adults and pediatric patients meeting labeled age requirements. Rizatriptan benzoate is the salt form used in commercial oral products.

The ODT is placed on the tongue, where it disintegrates without water. The dosage form is intended to improve convenience, not to create a fundamentally different pharmacokinetic pathway. Rizatriptan is absorbed systemically through the gastrointestinal tract after swallowing dissolved drug. The ODT should not be marketed as a buccal or sublingual delivery system unless the sponsor develops supporting clinical and regulatory evidence.

Attribute	Rizatriptan benzoate ODT
Therapeutic class	Triptan antimigraine agent
Dosage form	Orally disintegrating tablet
Common strengths	5 mg and 10 mg rizatriptan equivalent
Reference product	Maxalt-MLT
Administration	On the tongue without water
Regulatory pathway	Abbreviated New Drug Application for a generic product
Biosimilar exposure	None; rizatriptan is a small molecule
Primary formulation risks	Taste, friability, moisture uptake, dose uniformity, disintegration
Main commercial competitors	Generic rizatriptan tablets and ODTs, sumatriptan, eletriptan, zolmitriptan, ubrogepant, rimegepant

FDA labeling states that the reference ODT contains gelatin, mannitol, glycine, aspartame, and peppermint flavor as inactive ingredients.[1]

What excipients are used in the reference rizatriptan ODT?

The reference excipient system is designed around rapid wetting, porous structure, acceptable mouthfeel, and flavor masking.

Excipient	Functional role	Commercial implication
Gelatin	Matrix former and structural support in a rapidly disintegrating tablet	Raises animal-origin, vegetarian, religious, and supply-chain issues
Mannitol	Bulking agent, sweetener, cooling mouthfeel	Well established in ODTs; can improve palatability
Glycine	Matrix and taste-related excipient	May support mouthfeel and rapid disintegration
Aspartame	High-intensity sweetener	Creates a phenylketonuria labeling requirement
Peppermint flavor	Flavor masking	Must control intensity and compatibility with packaging

The reference product is associated with a freeze-dried or highly porous ODT architecture. That design can produce rapid dispersion in the mouth but may require specialized manufacturing, handling controls, and protective packaging.

A generic developer does not need to duplicate the reference formulation qualitatively or quantitatively in every case. The target is pharmaceutical equivalence and bioequivalence, together with compliance with applicable inactive-ingredient and dosage-form requirements. The formulation must also deliver the same labeled route, strength, dosage form, and administration instructions.

How should an excipient strategy be designed for rizatriptan ODT?

The strongest strategy separates the formulation into five functions: drug loading, tablet structure, disintegration, taste masking, and moisture protection.

Drug loading and salt selection

Rizatriptan benzoate is water soluble enough for conventional immediate-release development, but the salt and microenvironment can affect taste, stability, and dissolution. Developers should avoid unnecessary conversion to free base unless there is a clear manufacturing or sensory advantage.

The formulation should control:

• Rizatriptan benzoate assay and content uniformity
• Salt purity and polymorphic behavior
• Blend segregation at the low dose
• Interaction with alkaline or acidic excipients
• Dissolution across relevant pH conditions
• Degradation under high humidity

The 5 mg strength creates a greater risk of content-uniformity failure because the active represents a small fraction of total tablet mass. Geometric dilution, ordered mixing, or granulation may be preferable to simple low-shear blending.

Structural excipients

Mannitol is the leading commercial choice because it provides a clean mouthfeel, low hygroscopicity relative to many polyols, and broad use in ODT products. Microcrystalline cellulose can improve compact strength in direct-compression systems, but excessive use can create a gritty mouthfeel or slow wetting.

Crospovidone, croscarmellose sodium, and sodium starch glycolate can accelerate liquid penetration. Crospovidone is often attractive where fast wicking and low gelling are priorities. Superdisintegrant levels must be optimized against friability, tablet hardness, and mouthfeel.

A co-processed excipient platform can reduce development time. Mannitol-based ODT excipient systems containing a binder and disintegrant can support direct compression and reduce dependence on freeze-drying equipment.

Taste masking

Rizatriptan can produce an unpleasant taste if the drug dissolves rapidly in saliva. Sweetener alone may not be sufficient. A commercial taste-masking program can use:

• Polymer coating of drug particles
• Ion-exchange resin complexes
• Lipid or wax matrices
• Cyclodextrin complexes
• pH-modifying microenvironments
• Flavored, porous tablet matrices
• Combination sweetener systems

Taste masking must not delay the intended immediate-release dissolution profile. A coating that improves sensory performance but reduces dissolution can create bioequivalence and product-performance risks.

Aspartame is effective and familiar in ODTs but limits market access for patients with phenylketonuria. Acesulfame potassium, sucralose, saccharin sodium, neotame, or steviol glycosides can support an aspartame-free positioning. The choice should be based on residual bitterness, aftertaste, hygroscopicity, and regulatory acceptability.

Gelatin-free and vegetarian design

A gelatin-free product can capture pharmacies and consumers seeking vegetarian or non-animal-derived dosage forms. Alternatives include:

• Pullulan
• Hypromellose
• Polyvinyl alcohol
• Maltodextrin
• Microcrystalline cellulose
• Mannitol-based direct-compression matrices

A gelatin-free direct-compression ODT may reduce manufacturing complexity compared with a lyophilized wafer. The tradeoff is that the tablet must achieve low disintegration time without becoming fragile during bottling, shipping, and patient handling.

Moisture control

Moisture is a central development issue. It can cause:

• Loss of mechanical strength
• Premature disintegration
• Stickiness
• Flavor migration
• Drug degradation
• Packaging failures

Aluminum-aluminum blister packaging provides stronger moisture protection than standard high-density polyethylene bottles. Unit-dose blister packaging also protects the tablet during dispensing and improves portability, although it increases packaging cost.

A commercial formulation should be evaluated under accelerated and long-term stability conditions in the final marketed package. Packaging selection should occur before pivotal stability batches, not after formulation lock.

Which excipient platforms offer the best commercial opportunity?

Three formulation platforms are commercially credible.

Platform	Advantages	Main risks	Best positioning
Lyophilized porous tablet	Very rapid disintegration; close sensory experience to reference product	Fragility, higher manufacturing cost, specialized packaging	Premium ODT or reference-like product
Direct-compression mannitol ODT	Lower capital cost, scalable, simpler supply chain	Hardness, friability, taste, disintegration balance	Cost-focused generic
Taste-masked particulate ODT	Stronger control of bitterness and patient acceptability	More complex process and dissolution development	Differentiated product for adherence and repeat use

The most attractive first-to-market approach is usually a direct-compression, mannitol-based, aspartame-free and gelatin-free tablet. It can avoid the reference product’s animal-derived matrix and provide a clear label-level differentiation without requiring a novel delivery claim.

A second product can use a taste-masked formulation or a more robust porous architecture. That approach has greater technical value but also greater development cost.

What FDA regulatory status applies to rizatriptan benzoate ODT?

Rizatriptan products are regulated as small-molecule prescription drugs. The reference product received FDA approval under an NDA, and generic products generally enter through an ANDA demonstrating pharmaceutical equivalence and bioequivalence.[1,2]

A generic ODT typically must match the reference product in:

• Active ingredient
• Strength
• Dosage form
• Route of administration
• Performance characteristics
• Labeling, subject to permitted generic labeling changes

The sponsor must address ODT-specific quality attributes, including disintegration, dissolution, tablet strength, friability, water activity, moisture uptake, and dose uniformity. FDA guidance on orally disintegrating tablets identifies rapid disintegration and acceptable mechanical properties as core development considerations.[3]

A 505(b)(2) application could be relevant for a materially different formulation or delivery technology, but it is less efficient than an ANDA when the proposed product is a conventional generic ODT with the same active ingredient, strength, route, and dosage form.

What is the Orange Book and patent status of Maxalt-MLT?

Maxalt and Maxalt-MLT are legacy products with generic competition. The principal commercial exclusivity associated with rizatriptan has expired, and the market is no longer protected by the type of active U.S. patent estate that would normally prevent ANDA entry.

Issue	Commercial assessment
Core compound exclusivity	Expired
Reference-product market protection	Expired or no longer commercially blocking
Orange Book patent risk	Low for conventional rizatriptan ODT development
Formulation patent risk	Requires claim-by-claim review; low for the legacy reference formulation
Paragraph IV exposure	Possible in historical ANDA filings, but not a material barrier to ordinary current development
Biosimilar risk	Not applicable
Settlement risk	No widely recognized current settlement blocking ordinary generic entry

The Orange Book remains the controlling source for listed patents, exclusivity, and reference-product information.[2] Historical patent records should be reviewed by jurisdiction and claim scope because expired compound patents do not eliminate possible risks from later formulation, manufacturing, or method-of-use patents.

A developer should separate three patent questions:

1. Whether any unexpired patent covers rizatriptan itself.
2. Whether any unexpired patent covers a specific ODT formulation or manufacturing process.
3. Whether any method-of-use patent could affect the proposed label.

For a conventional immediate-release rizatriptan benzoate ODT, the principal IP risk is unlikely to be the active ingredient. It is more likely to arise from a deliberately differentiated excipient system, taste-masking technology, proprietary packaging, or a third-party platform license.

What formulation patents could protect a new rizatriptan ODT?

A new formulation may generate patentable subject matter in four areas.

Taste-masked particles

Claims may cover a coated rizatriptan particle, a particular polymer ratio, a particle-size distribution, or a dissolution profile that reduces bitterness while maintaining rapid release.

Direct-compression systems

Claims may focus on specific ratios of mannitol, crospovidone, binder, lubricant, and sweetener. Broad excipient claims are difficult to defend when the ingredients are standard ODT materials. Narrow process and performance claims may be more practical.

Moisture-resistant packaging

Packaging claims may cover a blister configuration, desiccant-integrated system, or moisture-control architecture. These rights are usually less valuable than composition claims but can support product differentiation.

Patient-specific compositions

Aspartame-free, gelatin-free, sugar-free, or allergen-reduced formulations can support method and composition claims if the formulation produces an unexpected technical result. A mere substitution of one common sweetener for another may face obviousness challenges.

Patent strength will depend on claim breadth, experimental support, prior-art density, and whether the claims distinguish the product from standard ODT platforms. The strongest filings generally combine composition claims with process, dissolution, stability, and packaging claims.

How does rizatriptan ODT compare with competing migraine products?

Rizatriptan ODT competes across two markets: low-cost generic triptans and newer branded migraine therapies.

Product category	Commercial advantage	Limitation versus rizatriptan ODT
Rizatriptan conventional tablet	Low cost and mature supply	Requires water and swallowing
Rizatriptan ODT	Portable, water-free administration	Taste and moisture sensitivity
Sumatriptan products	Broad availability and multiple dosage forms	Different efficacy and tolerability profile
Zolmitriptan nasal or ODT	Alternative administration options	Higher cost or stronger sensory challenges
Ubrogepant and rimegepant	Non-triptan options for patients with triptan limitations	Higher price and branded or recently genericizing market conditions
Nasal or injectable migraine products	Rapid administration and utility during nausea	Higher cost, device complexity, and patient acceptance barriers

Rizatriptan ODT is commercially strongest where patients value convenience but payers prioritize generic pricing. It is less differentiated clinically than newer CGRP-targeting products, so the formulation and distribution strategy must carry much of the product value.

What commercial opportunities exist for rizatriptan benzoate ODT?

The opportunity is primarily a manufacturing and market-access opportunity rather than a basic patent-monopoly opportunity.

Private-label and authorized-generic supply

A reliable supplier can serve pharmacy chains, wholesalers, telehealth platforms, and regional generic distributors. The product has a simple chronic supply model: migraine treatment is intermittent, but patients often refill through the same pharmacy.

Product-line expansion

A manufacturer with existing migraine products can add rizatriptan ODT in 5 mg and 10 mg strengths. The same commercial infrastructure can support conventional rizatriptan tablets or other triptans.

Differentiated labeling

An aspartame-free and gelatin-free product can target patients who avoid the reference excipients. The label should avoid unsupported superiority claims. The commercial message can focus on ingredient profile, portability, and water-free administration.

Emerging-market and geographic supply

Rizatriptan ODT can be attractive in markets where blister-packed, water-free medicines are valued but branded CGRP products remain expensive. Geographic opportunities depend on local registration, reference-product requirements, patent status, and reimbursement.

Contract development and manufacturing

The product is suitable for CDMO offerings because the underlying active ingredient is established and the key technologies, including direct compression, taste masking, and high-barrier packaging, are transferable to other ODT products.

What generic launch risks exist for rizatriptan ODT?

The main risks are operational rather than exclusivity-driven.

Risk	Impact	Mitigation
Tablet friability	Product loss and patient complaints	Optimize compression, binder, and packaging
Slow disintegration	Failure to match ODT performance	Use disintegration testing in saliva-relevant conditions
Bitterness	Poor repeat use and weaker pharmacy acceptance	Conduct human sensory screening and taste-masking development
Moisture sensitivity	Stability failure	Use high-barrier unit-dose packaging
Low-dose blend segregation	Assay and content-uniformity failures	Use validated blending and granulation controls
Sweetener restrictions	Limited patient access	Develop aspartame-free alternative
Gelatin sourcing	Supply and labeling limitations	Use a gelatin-free platform
ANDA deficiency	Delayed launch	Align formulation, dissolution, bioequivalence, and labeling strategy early

How strong is the patent estate for a new rizatriptan ODT?

The legacy rizatriptan product estate is commercially weak as a barrier to a conventional generic ODT because the compound and principal reference-product exclusivities are old. A new sponsor can create a narrower, product-specific estate through:

• Taste-masked rizatriptan particles
• Aspartame-free formulations
• Gelatin-free porous matrices
• Moisture-resistant packaging
• Manufacturing processes that improve tablet robustness
• Defined disintegration and dissolution profiles

These rights are more likely to protect a specific commercial product than the broader rizatriptan ODT category. Freedom-to-operate analysis should focus on active claims in the United States, Europe, Canada, Japan, and target emerging markets. Patent term adjustment, supplementary protection certificates, national phase status, and terminal disclaimers can change the practical expiration analysis.

Key Takeaways

• Rizatriptan benzoate ODT is a mature small-molecule generic opportunity with low core patent risk.
• Maxalt-MLT uses gelatin, mannitol, glycine, aspartame, and peppermint flavor.
• The strongest product differentiation is likely to come from an aspartame-free, gelatin-free, moisture-protected formulation.
• Direct compression offers the best balance of cost, scalability, and commercial flexibility.
• Lyophilized tablets can provide rapid disintegration but carry higher fragility and packaging costs.
• Taste masking is a central technical and commercial issue.
• The main regulatory pathway is an ANDA, provided the product remains pharmaceutically equivalent to the reference product.
• Biosimilar risk does not apply because rizatriptan is a small molecule.
• New patent value is most likely to arise from formulation, process, taste-masking, and packaging claims.
• Generic launch risk is driven more by product quality and supply reliability than by compound exclusivity.

FAQs

Can rizatriptan benzoate ODT be made without aspartame?

Yes. A formulation can use sucralose, acesulfame potassium, saccharin sodium, or another suitable sweetener. The developer must demonstrate acceptable taste, stability, dissolution, and labeling compliance.

Is gelatin required in a rizatriptan ODT?

No. Gelatin is used in the reference product’s matrix, but a generic formulation can use direct compression or alternative polymeric matrix systems if the resulting product meets regulatory performance requirements.

Does an ODT version of rizatriptan provide faster systemic absorption?

Not necessarily. An ODT can improve administration convenience and disintegration in the mouth, but the clinical pharmacokinetic benefit must be demonstrated rather than assumed.

What packaging is most suitable for rizatriptan ODT?

High-barrier aluminum-aluminum blister packaging is generally the strongest option for protecting a moisture-sensitive ODT. Bottles may be viable if moisture protection and tablet robustness are adequately demonstrated.

Can a new rizatriptan ODT obtain formulation patents?

Potentially, but broad claims based only on substituting common ODT excipients may be vulnerable to prior art and obviousness challenges. Stronger opportunities may involve a defined taste-masking architecture, unexpected stability result, specific manufacturing process, or integrated packaging system.

References

1. U.S. Food and Drug Administration. (2023). Maxalt-MLT (rizatriptan benzoate) orally disintegrating tablets: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2008). Guidance for industry: Orally disintegrating tablets.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
5. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products.
6. United States Pharmacopeia. (2024). General chapter <701> disintegration. USP-NF.